Update on omalizumab in allergen immunotherapy
JA Dantzer, RA Wood - Current opinion in allergy and clinical …, 2021 - journals.lww.com
JA Dantzer, RA Wood
Current opinion in allergy and clinical immunology, 2021•journals.lww.comOmalizumab in conjunction with immunotherapy has shown promising results for the
treatment of allergic rhinitis, venom hypersensitivity, and food allergy, especially in the
reduction of adverse events. Larger randomized, placebo-controlled trials are needed to
better understand optimal dosing and duration, cost-–benefit analysis, ideal patients, and
long-term benefits. This combination therapy has the potential to improve treatment,
particularly for high–risk patients.
treatment of allergic rhinitis, venom hypersensitivity, and food allergy, especially in the
reduction of adverse events. Larger randomized, placebo-controlled trials are needed to
better understand optimal dosing and duration, cost-–benefit analysis, ideal patients, and
long-term benefits. This combination therapy has the potential to improve treatment,
particularly for high–risk patients.
Summary
Omalizumab in conjunction with immunotherapy has shown promising results for the treatment of allergic rhinitis, venom hypersensitivity, and food allergy, especially in the reduction of adverse events. Larger randomized, placebo-controlled trials are needed to better understand optimal dosing and duration, cost-–benefit analysis, ideal patients, and long-term benefits. This combination therapy has the potential to improve treatment, particularly for high–risk patients.
Lippincott Williams & Wilkins